UK-based GlaxoSmithKline PLC (GB:GSK) has won the latest U.S. trial concerning its heartburn drug Zantac (ranitidine), amid litigation over alleged cancer risks. The Florida State Court ruled in ...

GSK and other drugmakers fending off litigation claiming that gastrointestinal drug Zantac or a generic caused cancer have won a supreme court ruling in Canada, after also chalking up wins in the US.

British pharmaceutical group GSK on Friday welcomed victory in drawn out US litigation regarding its Zantac drug for heartburn that allegedly caused cancer. The over-the-counter treatment ...

GSK shares jumped ... claims its Zantac heartburn drug causes cancer. The Delaware Supreme Court said it will review a decision by a lower court to let an upcoming trial hear evidence from ...

Delaware’s top court is set to hear an appeal from GSK and other pharmaceutical ... In December 2022, approximately 50,000 Zantac cases were dismissed during a pre-trial hearing in Florida.

More than 300 million people around the world suffer from COPD, with about 40% exhibiting the type of inflammation affecting patients in GSK’s latest trial, according to the company. The disease ...

Healthcare & Pharmaceuticalscategory EU regulator backs use of GSK's RSV shot in adults aged 50 to 59 July 26, 2024 Reuters, the news and media division of Thomson Reuters, is the world’s ...

(RTTNews) - GSK plc (GSK, GSK.L) announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL ...

(Sharecast News) - GSK announced positive results from its phase three 'MATINEE' clinical trial on Friday, which evaluated the effectiveness of 'Nucala', or mepolizumab, in treating chronic ...

Proactive Investors - GSK PLC (LON:GSK) announced positive results from a Phase III clinical trial, MATINEE, evaluating Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD). The trial ...